Researchers trained machine learning (ML) models to analyze RNA molecular signatures in patients’ blood.
Hims’ push into compounded GLP-1 drugs risks scrutiny from Novo Nordisk
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) The digital health company Hims & Hers